Tweet
This is the only supplement I take (other than extra fiber). Grr. - Dave
Vitamin D status does not influence disability progression of multiple sclerosis patients over three years follow-up
A.-H. Muris1,2, J. Smolders2, L. Rolf1,2, L. Klinkenberg3, N. van der Linden3, S. Meex3, J. Damoiseaux3, R. Hupperts1,2
1School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, 2Academic MS Center Limburg, Orbis Medical Center, Sittard, 3Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands
Introduction: The risk of developing multiple sclerosis (MS) as well as MS disease activity is associated with vitamin D (25(OH)D) status. The relationship between the main functional disability hallmark of MS, disability progression, and 25(OH)D status is less well established though, especially not in progressive MS patients.
Methods: This retrospective 3-year follow-up study included 554 MS patients with a baseline 25(OH)D serum level and Expanded Disability Status Scale (EDSS) with a minimum follow-up of three years. Logistic regressions were performed to assess the effect of baseline 25(OH)D on relapse rate. Repeated measures linear regression analyses were performed to assess the effect on disability and disability progression.
Results: Baseline deseasonalized 25(OH)D status was associated with subsequent relapse risk (yes/no), but only in the younger MS patients (≤ 37.5 years; OR=0.872, per 10nmol/L 25(OH)D, p=0.041). Baseline 25(OH)D was not significantly associated with either disability or disability progression, irrespective of MS phenotype.
Discussion and conclusion: Within the physiological range, 25(OH)D status appears to affect the occurrence of relapses in younger MS patients, but does not significantly diminish disability or disability progression. Whether high dose supplementation to supra physiological 25(OH)D levels prevents disability progression in MS should become clear from long term follow-up of supplementation studies.
Vitamin D status does not influence disability progression of multiple sclerosis patients over three years follow-up
A.-H. Muris1,2, J. Smolders2, L. Rolf1,2, L. Klinkenberg3, N. van der Linden3, S. Meex3, J. Damoiseaux3, R. Hupperts1,2
1School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, 2Academic MS Center Limburg, Orbis Medical Center, Sittard, 3Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands
Introduction: The risk of developing multiple sclerosis (MS) as well as MS disease activity is associated with vitamin D (25(OH)D) status. The relationship between the main functional disability hallmark of MS, disability progression, and 25(OH)D status is less well established though, especially not in progressive MS patients.
Methods: This retrospective 3-year follow-up study included 554 MS patients with a baseline 25(OH)D serum level and Expanded Disability Status Scale (EDSS) with a minimum follow-up of three years. Logistic regressions were performed to assess the effect of baseline 25(OH)D on relapse rate. Repeated measures linear regression analyses were performed to assess the effect on disability and disability progression.
Results: Baseline deseasonalized 25(OH)D status was associated with subsequent relapse risk (yes/no), but only in the younger MS patients (≤ 37.5 years; OR=0.872, per 10nmol/L 25(OH)D, p=0.041). Baseline 25(OH)D was not significantly associated with either disability or disability progression, irrespective of MS phenotype.
Discussion and conclusion: Within the physiological range, 25(OH)D status appears to affect the occurrence of relapses in younger MS patients, but does not significantly diminish disability or disability progression. Whether high dose supplementation to supra physiological 25(OH)D levels prevents disability progression in MS should become clear from long term follow-up of supplementation studies.